KEGG   DRUG: Casirivimab and imdevimab
Entry
D12142            Mixture   Drug                                   
Name
Casirivimab and imdevimab;
Casirivimab (genetical recombination) and imdevimab (genetical recombination);
Regen-cov (TN);
Ronapreve (TN)
Component
Casirivimab [DR:D11938], Imdevimab [DR:D11939]
Class
Antiviral
 DG03174  Anti-SARS-CoV-2 agent
Remark
Therapeutic category: 6250
Product: D12142<JP>
Efficacy
Antiviral
Target
SARS-CoV-2 spike glycoprotein [KO:K24152]
  Pathway
ko03230  Viral genome structure
ko05171  Coronavirus disease - COVID-19
Brite
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D12142  Casirivimab and imdevimab
Drug groups [BR:br08330]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12142  Casirivimab and imdevimab
Drug classes [BR:br08332]
 Antiviral
  DG03174  Anti-SARS-CoV-2 agent
   D12142  Casirivimab and imdevimab
Antimicrobials [BR:br08307]
 Antivirals
  Entry, fusion or uncoating inhibitor
   Coronavirus spike protein
    D12142  Casirivimab and imdevimab <JP>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12142
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D12142
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D12142
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system